1616287-82-1

Basic information

• Product Name: 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one
• CAS NO: 1616287-82-1
• Molecular Weight: 446.333
• Mol File: 1616287-82-1.mol

Chemical Properties

• CAS DataBase Reference: 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one(1616287-82-1)
• EPA Substance Registry System: 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one(1616287-82-1)

Safety Data

• Hazardous Substances Data: 1616287-82-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one is used as a potential pharmaceutical agent for its possible interaction with biological targets. 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one's diverse functional groups may allow it to modulate various biological pathways and processes, offering a wide range of therapeutic applications that require further investigation.
Used in Biological Research:
In the field of biological research, 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one serves as a valuable tool for studying the interactions between small molecules and biological systems. Its complex structure provides opportunities to explore its binding affinity, selectivity, and potential effects on cellular functions, contributing to the advancement of our understanding of molecular biology and pharmacology.

Upstream product

• 832114-00-8 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole 
• 1616289-36-1 2-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-7-bromo-5,8-dichloro-3,4-dihydroiso-quinolin-1(2H)-one 
• 3218-50-6 2-(2,5-dichlorophenyl)acetonitrile 
• 1616289-30-5 ethyl 3,6-dichloro-2-methyl-benzoate 
• 7499-08-3 3-chloro-2-methylbenzoic acid 
• 1303445-99-9 2-(benzyloxy)-3-(chloromethyl)-4,6-dimethylpyridine 
• 1616289-37-2 2-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1616289-35-0 7-bromo-5,8-dichloro-3,4-dihydroisoquinolin-1(2H)-one 
• 1616289-34-9 5,8-dichloro-3,4-dihydroisoquinolin-1(2H)-one 
• 1616289-32-7 ethyl 3,6-dichloro-2-(cyanomethyl)benzoate 
• 1616289-31-6 ethyl 2-(bromomethyl)-3,6-dichloro-benzoate 
• 1918-01-0 3,6-dichloro-2-methyl-benzoic acid 
• 1306439-42-8 [2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methanol 
• 721959-71-3 2-(benzyloxy)-4,6-dimethylpyridine-3-carbaldehyde 

Relevant articles and documents

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors

A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted phenyl ring joined to a dimethylpyridone moiety via an amide linkage has been designed. A preferential amide torsion that improved the binding properties of the compounds was identified for this series via computational analysis. Cyclization of the amide linker resulted in a six-membered lactam analogue, compound 18. This transformation significantly improved the ligand efficiency/potency of the cyclized compound relative to its acyclic analogue. Additional optimization of the lactam-containing EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compound 31. Compound 31 displayed improved LipE and on-target potency in both biochemical and cellular readouts relative to compound 18. Inhibitor 31 also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.

ARYL AND HETEROARYL FUSED LACTAMS

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.